SVSylvia M. C. Vijgen

Sylvia M. C. Vijgen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sylvia M. C. Vijgen has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Brent C. Opmeer

    Department of Obstetrics and Gynecology Academic Medical Center Amsterdam the Netherlands

    4 shared publications
  • Anneke Kwee

    University Medical Center Utrecht The Netherlands

    3 shared publications
  • Christine Willekes

    GROW‐School for Oncology and Developmental Biology Maastricht University Medical Center Maastricht the Netherlands

    3 shared publications
  • Ben Willem J. Mol

    2 shared publications
  • Denise Bijlenga

    Department of Obstetrics and Gynecology Academic Medical Center Amsterdam the Netherlands

    2 shared publications
  • Jan G. Nijhuis

    GROW‐School for Oncology and Developmental Biology Maastricht University Medical Center Maastricht the Netherlands

    2 shared publications

Latest Publications

  • Economic analysis comparing induction of labor and expectant management in women with preterm prelabor rupture of membranes between 34 and 37 weeks (PPROMEXIL trial)

    by Sylvia M. C. Vijgen, David P. van der Ham, Denise Bijlenga, Johannes J. van Beek, Kitty W. M. Bloemenkamp, Anneke Kwee, Mariët Groenewout, Michael M. Kars, Simone Kuppens, Gerald Mantel, et al.

    Objective: To compare the costs of induction of labor and expectant management in women with preterm prelabor rupture of membranes (PPROM).Design: Economic analysis based on a randomized clinical trial.Setting: Obstetric departments of eight academic and 52 non‐academic hospitals in the Netherlands.Population: Women withPPROMnear term who were not in labor 24 h afterPPROM.Methods: A cost‐minimization analysis was done from a health care provider perspective, using a bottom‐up approach to estimate resource utilization, valued with unit‐costs reflecting actual costs.Main outcome measures: Primary health outcome was the incidence of neonatal sepsis. Direct medical costs were estimated from start of randomization to hospital discharge of mother and child.Results: Induction of labor did not significantly reduce the probability of neonatal sepsis [2.6% vs. 4.1%, relative risk 0.64 (95% confidence interval 0.25–1.6)]. Mean costs per woman were €8094 for induction and €7340 for expectant management (difference €754; 95% confidence interval −335 to 1802). This difference predominantly originated in the postpartum period, where the mean costs were €5669 for induction vs. €4801 for expectant management. Delivery costs were higher in women allocated to induction than in women allocated to expectant management (€1777 vs. €1153 per woman). Antepartum costs in the expectant management group were higher because of longer antepartum maternal stays in hospital.Conclusions: In women with pregnancies complicated byPPROMnear term, induction of labor does not reduce neonatal sepsis, whereas costs associated with this strategy are probably higher.


  • Economic analysis comparing induction of labour and expectant management for intrauterine growth restriction at term (DIGITAT trial)

    by Sylvia M.C. Vijgen, Kim E. Boers, Brent C. Opmeer, Denise Bijlenga, Dick J. Bekedam, Kitty W.M. Bloemenkamp, Karin de Boer, Henk A. Bremer, Saskia le Cessie, Friso M.C. Delemarre, et al.


  • Economic evaluation studies in reproductive medicine: a systematic review of methodologic quality

    by Lobke M. Moolenaar, Sylvia M.C. Vijgen, Peter Hompes, Fulco van der Veen, Ben Willem J. Mol, Brent C. Opmeer


  • The Methodological Quality of Economic Evaluation Studies in Obstetrics and Gynecology: A Systematic Review

    by Brent C. Opmeer, Ben Willem J. Mol, Sylvia M.C. Vijgen

    We evaluated the methodological quality of economic evaluation studies in the field of obstetrics and gynecology published in the last decade. A MEDLINE search was performed to find economic evaluation studies in obstetrics and gynecology from the years 1997 through 2009. We included full economic evaluation studies concerning tests or interventions in the field of obstetrics or gynecology. Each included study was evaluated by two reviewers using a quality checklist that was based on international guidelines for medical economic evaluation studies and a checklist used in a previous review. The mean number of quality criteria adhered to was 23 of 30 items, whereas five articles (3%) met all 30 criteria. Compliance was low for the description of the perspective (40%), the completeness of costs looking at the perspective (48%) or time horizon (48%), and reporting of quantities of resources (47%). Furthermore, if no discounting was applied, an explanation was infrequently given (14%). A comparison of study quality to that reported by Smith and Blackmore showed a considerable improvement in the following criteria: presentation perspective (from 19 to 40%), statement of primary outcome measure (from 72 to 81%), completeness costs looking at the time horizon (from 14 to 48%), the presentation of discount rates (from 10 to 54%), details of sensitivity analyses (from 21 to 61%), reporting incremental results (from 17 to 70%), and reporting a summary measure (from 57 to 74%). The quality of economic studies in obstetrics and gynecology has considerably improved in the last decade, but room for further improvement is present.


  • Cost-effectiveness of cardiotocography plus ST analysis of the fetal electrocardiogram compared with cardiotocography only

    by Sylvia M.C. Vijgen, Michelle E.M.H. Westerhuis, Brent C. Opmeer, Gerard H.A. Visser, Karl G.M. Moons, Martina M. Porath, Guid S. Oei, Herman P. VAN Geijn, Antoinette C. Bolte, Christine Willekes, et al.

    To assess the cost-effectiveness of addition of ST analysis of the fetal electrocardiogram (ECG; STAN) to cardiotocography (CTG) for fetal surveillance during labor compared with CTG only. Cost-effectiveness analysis based on a randomized clinical trial on ST analysis of the fetal ECG. Obstetric departments of three academic and six general hospitals in The Netherlands. Population. Laboring women with a singleton high-risk pregnancy, a fetus in cephalic presentation, a gestational age >36 weeks and an indication for internal electronic fetal monitoring. A trial-based cost-effectiveness analysis was performed from a health-care provider perspective. Primary health outcome was the incidence of metabolic acidosis measured in the umbilical artery. Direct medical costs were estimated from start of labor to childbirth. Cost-effectiveness was expressed as costs to prevent one case of metabolic acidosis. The incidence of metabolic acidosis was 0.7% in the ST-analysis group and 1.0% in the CTG-only group (relative risk 0.70; 95% confidence interval 0.38-1.28). Per delivery, the mean costs per patient of CTG plus ST analysis (n= 2 827) were €1,345 vs. €1,316 for CTG only (n= 2 840), with a mean difference of €29 (95% confidence interval -€9 to €77) until childbirth. The incremental costs of ST analysis to prevent one case of metabolic acidosis were €9 667. The additional costs of monitoring by ST analysis of the fetal ECG are very limited when compared with monitoring by CTG only and very low compared with the total costs of delivery.